Crenolanib in D842V mutant GIST
About the ARO-012 CrenoGIST study for D842V mutant GIST:
- This is a Phase III clinical trial of crenolanib in patients with advanced or metastatic gastrointestinal stromal tumors (GIST) with a specific abnormality in a gene called PDGFRA-D842V which is now recruiting at multiple centers in the United States and Europe.
- This study is being done to find out how safe and effective an investigational drug called crenolanib is, compared with a placebo, in prolonging the time people with a specific type of GIST live without their GIST getting worse.
- Crenolanib is a type of drug known as a Tyrosine Kinase Inhibitor (TKI). Crenolanib is an investigational product, which is a drug that has not been approved by the U.S. Food and Drug Administration (FDA) or other regulatory agencies.
For more information about the study, please contact a study site or visit clinicaltrials.gov/ct2/show/NCT02847429
You may qualify for this study if:
- You have advanced or metastatic GIST which carries the PDGFRA D842V genetic mutation, and
- You have GIST which is measurable and progressing by CT or MRI scan
You are allowed to have had other Tyrosine Kinase Inhibitors, such as imatinib, before this study.
If you might be interested in participating in the ARO-012 CrenoGIST study, you are encouraged to speak with your doctor and your friends and family.